Compass Pathways Prepared Psilocybin Therapy Submission
The company is seeking FDA approval for a synthetic psilocybin treatment for those with treatment-resistant depression.
Updated on Oct. 15, 2026 in Mental Health
Live Poll
Should new psychedelic therapies be rolled out slowly to ensure safety despite the need for access?
Compass Pathways is finalizing a rolling FDA submission for COMP360, a synthetic psilocybin treatment designed for treatment-resistant depression. The rollout is planned for early next year if the company receives the necessary regulatory approval.
Why it matters
This development represents a potential new pathway for individuals with depression that has not responded to traditional therapies. The company is actively working with insurers and regulators to manage the complex administration requirements for the drug.
In Phase 3 trials, 25% of patients experienced a clinically meaningful response after a single administration of COMP360, while 40% responded after a second dose. It remains unknown if this efficacy will translate to real-world outcomes following regulatory review.
The players
Compass Pathways
A biotechnology company focused on mental health care and developing psychedelic-derived treatments for depression.
Lykos Therapeutics
A biopharmaceutical company developing MDMA-assisted therapies that faced a recent FDA rejection.
Centers for Medicare and Medicaid Services
A federal agency within the U.S. Department of Health and Human Services that oversees healthcare reimbursement policies.
The details
The treatment involves a six-hour supervised session, during which silence accounts for approximately 80% of the time. Patients who achieve a response may see benefits last up to one year after two or three administrations. The company is currently investing in provider training to ensure consistent administration and is coordinating with the Centers for Medicare and Medicaid Services regarding reimbursement for patient monitoring.
Timeline
2024: The FDA rejected an MDMA-based therapy from Lykos Therapeutics.
Q4 2026: Compass Pathways expects to complete its rolling FDA submission.
Early 2027: The company plans to launch COMP360 following potential approval.
Health Landscape
This submission follows the regulatory pattern set by the 2024 FDA rejection of Lykos Therapeutics MDMA-based therapy. The move reflects the broader push to establish clinical standards for psychedelic-assisted medicine within the current regulatory environment.
For those managing treatment-resistant depression, this development highlights a potential future option that requires intensive, supervised clinical support. If you are interested in how emerging therapies might eventually fit into your care plan, that is a topic to discuss with your physician.
The takeaway
The potential approval of COMP360 could offer a long-term benefit for patients who have not found success with standard antidepressants. Patients should continue working with their current care team to manage existing symptoms while awaiting updates on new treatment options.
Further reading
You can find more coverage on emerging clinical options in Mental Health.
Source note: This article includes information reported by STAT.
Live Poll
Should new psychedelic therapies be rolled out slowly to ensure safety despite the need for access?
